Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2025-12-25 @ 9:10 PM
Study NCT ID:
NCT07206056
Status:
RECRUITING
Last Update Posted:
2025-11-25
First Post:
2025-09-17
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Sponsor:
Novartis Pharmaceuticals
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10-15
Start Date Type:
ACTUAL
Primary Completion Date:
2029-10-29
Primary Completion Date Type:
ESTIMATED
Completion Date:
2030-12-17
Completion Date Type:
ESTIMATED
First Submit Date:
2025-09-17
First Submit QC Date:
None
Study First Post Date:
2025-10-03
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-24
Last Update Post Date:
2025-11-25
Last Update Post Date Type:
ESTIMATED